Kadimastem Ltd.
KDST | TA
Overview
Corporate Details
- ISIN(s):
- IL0011284614
- LEI:
- Country:
- Israel
- Address:
- Pinchas Sapir 3, Weizmann Science Park, 7414003 Nes-Ziona
- Website:
- https://www.kadimastem.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Kadimastem develops cell therapy solutions for neurodegenerative diseases and diabetes.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2024-05-28 11:41 |
Investor Presentation
Company Presentation
|
English | 4.4 MB | |
| 2024-05-28 11:41 |
Investor Presentation
Company Presentation
|
Russian | 42.5 KB | |
| 2024-02-12 13:47 |
Regulatory News Service
Excellence Investments Management and Securities will cease to operate as a mar…
|
Hebrew (modern) | 122.7 KB | |
| 2022-12-13 16:05 |
Regulatory News Service
Rights Offering and Identifying Details for New Security-KADIMASTEM R4
|
Hebrew (modern) | 177.9 KB | |
| 2022-08-09 13:00 |
Regulatory News Service
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
|
English | 12.0 KB | |
| 2022-06-08 13:00 |
Regulatory News Service
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards …
|
English | 12.1 KB | |
| 2022-05-30 15:10 |
Regulatory News Service
Kadimastem Awarded Patent in Japan for AstroRx For ALS and Drug Screening
|
English | 10.6 KB | |
| 2022-05-18 13:00 |
Regulatory News Service
Kadimastem Expands R&D Program to Include Multiple Sclerosis
|
English | 9.5 KB | |
| 2022-03-03 14:05 |
Regulatory News Service
Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) f…
|
English | 10.4 KB | |
| 2021-12-13 13:00 |
Regulatory News Service
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel I…
|
English | 10.6 KB | |
| 2021-10-26 07:49 |
Capital/Financing Update
Kadimastem Raises $5 million In Private Placement
|
English | 10.5 KB | |
| 2021-10-25 14:09 |
Capital/Financing Update
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
|
English | 10.5 KB | |
| 2021-10-12 15:55 |
Inside Information Statement
Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT)
Regar…
|
English | 9.5 KB | |
| 2021-05-02 19:15 |
Investor Presentation
Company Presentation May 2021
|
English | 3.0 MB | |
| 2021-05-02 19:15 |
Company Presentation
Company Presentation May 2021
|
Russian | 42.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |